The purpose of this project is to establish the Victorian Melanoma and Clinical Trials Centre (VMCTC) integrated with Alfred Cancer and some of Alfred Research's functions. The proposed facility will be located at 545 St Kilda Road and will provide specialist, multidisciplinary care of patients with all stages of melanoma in a dedicated physical facility. The aim of the project is to design, construct and commission a dedicated stand-alone new facility that accommodates clinical services and research facilities.

The VMCTC Facility is a product of Alfred Health's desire for a singular highly visible centre for cancer treatment and research, supporting high-end research into cancer, and providing a patient centred experience. The building primarily hosts programs associated with cancer care and clinical trials, including being the home of the Victorian Melanoma Service, itself already a globally renowned centre of research and patient care.

The Architectural brief was to create a building that can be seen as an 'icon', representing a global centre of excellence in research in melanoma and other cancers, and one that will attract and retain the best researchers in the world to continue to forge the best ongoing treatments and preventative procedures for these diseases.

The VMCTC involves the construction of a new building comprising 2 basement levels and 7 above ground levels. In summary the scope of the project by level is as follows:

• Level B2 Parking Allocation
• Level B1 Ambulance & Visitor Drop Off, Parking Allocation, Staff End of Trip Facility, PET/CT Medical Imaging Suite, Plant & Substation
• Level GL Front of House, Wellness Centre, Back of House incl. Loading Dock
• Level 1 Specialist Consulting Suites inclusive of VECTRA imaging for VMS
• Level 2 Day Therapy Unit inclusive of Cancer related Day Treatment, Clinical Trials & Urgent Review Clinic
• Level 3 Delivered as a 'Cold Shell' Floor
• Level 4 Research Laboratories Clinical Trials Processing Lab, Cellular Therapy Unit incl. of CAR T-Cell Lab, Pharmacy, Dry lab & Collaborative Areas
• Level 5 Staff Workspace open work points and offices, Staff Collaboration Spaces and Staff Amenities
• Level 6 Enclosed Plant
• Level 7 Open Plant

Timing

Construction is due to commence in mid 2022 and be completed by the end of 2023/early 2024.

Local Content

The minimum level of local content set for this project is awaitingfinal Ministerial approval.

Project Website

Please Note - this is NOT an EOI for the Main Contractor as that process has already been undertaken by Alfred Health. However if you are a Sub-Contractor, Manufacturer and/or Product Supplier please provide an EOI as below.

HOW TO REGISTER AN EXPRESSION OF INTEREST (EOI)

To submit an initial EOI, companies must have an ICN Gateway company profile. Information on how to register your company on ICN Gateway is detailed below.
This is an initial, generic EOI submission only. All companies who submit an EOI will be included in information presented to Construction Companies who are shortlisted to bid for this Project.
The services, programmes and initiatives provided by ICN Victoria are aimed at complementing a company's existing Sales, Marketing and Business Development strategy and any EOI submitted should not be considered as an alternative to these activities.

ICN GATEWAY COMPANY REGISTRATION

Click hereto register your company profile on ICN Gateway.
Support and assistance is available through the web links listed below.
An ICN Gateway company profile that accurately and effectively summarises your company is critical to using the services of the ICN network - please ensure that your company invests the time and energy required to represent your company in the most effective manner possible.
Companies should ensure that the email notification functionality within their ICN Gateway company profile is activated to include an appropriate level of coverage to ICN Information and Updates, Major Projects and Regional Opportunities.
(1)ICN Gateway Setup Wizard

(2)ICN Gateway User Guide